Macular Edema News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Diabetic Macular Edema Vastly Undertreated, Real-World Data Suggest - Medscape



Medscape
 
Diabetic Macular Edema Vastly Undertreated, Real-World Data Suggest 
Medscape
NEW ORLEANS ? Most patients with newly diagnosed diabetic macular edema (DME) are inadequately treated, according to findings from the American Academy of Ophthalmology's IRIS Registry. "We found that DME patients are likely undertreated in the ...
IRIS Registry gives glimpse into DME in real world ModernMedicine

all 2 news articles » 


Data Suggest Undertreatment of Diabetic Macular Edema - MedPage Today



MedPage Today
 
Data Suggest Undertreatment of Diabetic Macular Edema 
MedPage Today
NEW ORLEANS -- Three-fourths of patients with newly diagnosed diabetic macular edema (DME) received no treatment during the first month after diagnosis, and 60% of them remained untreated for a year, data from a clinical registry suggested.

 


Diabetic Macular Edema Market Comprehensive Insights 2017 to 2025 - Research of Market



Diabetic Macular Edema Market Comprehensive Insights 2017 to 2025 
Research of Market
Diabetic Macular Edema (DME)-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Diabetic Macular Edema (DME). The report provides a complete understanding of ...
Diabetic Macular Edema Therapeutics Market Overview, Demand, Size, Growth & Forecast 2022- Worldwide Analysis satPRnews (press release)

all 3 news articles » 


Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical ... - Dove Medical Press



Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical ... 
Dove Medical Press
Purpose: To study vitreoretinal interface (VRI) abnormalities in diabetic macular edema (DME) and the influence of these on the effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) therapy. Methods: VRI status and central ...

 


Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal ... - Dove Medical Press



Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal ... 
Dove Medical Press
Methods: Twelve eyes of 9 patients with intermediate and posterior noninfectious inflammatory uveitis complicated with refractory macular edema were regularly reviewed after a dexamethasone intravitreal implant. Patients were examined at baseline, 30 ...

 


Diffuse Diabetic Macular Edema - Global Clinical Trials Review, H2, 2017 - Research and Markets - Business Wire (press release)



Diffuse Diabetic Macular Edema - Global Clinical Trials Review, H2, 2017 - Research and Markets 
Business Wire (press release)
The clinical trial report, Diffuse Diabetic Macular Edema Global Clinical Trials Review, H2, 2017" provides an overview of Diffuse Diabetic Macular Edema clinical trials scenario. This report provides top line data relating to the clinical trials on ...

and more » 


Steroid and NSAID combination prevents macular oedema after cataracts - ModernMedicine



Steroid and NSAID combination prevents macular oedema after cataracts 
ModernMedicine
A combination of a topical corticosteroid and a nonsteroidal anti-inflammatory drug (NSAID) is more effective than either one alone in reducing the risk of cystoid macular oedema (CME) after cataract surgery in nondiabetic patients, researchers say.

 


Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together ... - GlobeNewswire (press release)



Dispatch Tribunal
 
Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together ... 
GlobeNewswire (press release)
A consequence of diabetic retinopathy, DME is swelling in the area of the retina called the macula caused by leaking blood vessels. DME affects up to 30% of people who have had diabetes for 20 years or more, and if untreated, approximately 20 to 30% of ...
Clearside Biomedical, Inc. (CLSD) Upgraded to ?Hold? at Zacks Investment Research Dispatch Tribunal

all 14 news articles » 


Clearside Biomedical's Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular ... - GlobeNewswire (press release)



Clearside Biomedical's Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular ... 
GlobeNewswire (press release)
Clearside Biomedical's Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting ...
Clearside Biomedical, Inc. (CLSD) Upgraded to Hold by Zacks Investment Research StockNewsTimes

all 7 news articles » 


KalVista, Merck Partnership on Blindness Drug Sends Shares Skyward - Xconomy



Xconomy
 
KalVista, Merck Partnership on Blindness Drug Sends Shares Skyward 
Xconomy
Diabetic macular edema (DME) is a buildup of fluid in the macula, the central portion of the retina at the back of the eye, according to the nonprofit organization Prevent Blindness. It is a complication of diabetic retinopathy, an eye disease in which ...